Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+0.26%
+5.06%
+11.88%
+1.85%
+0.63%
EXAS
Exact Sciences
$53.06
Chart
43.66
50.59
57.55
54.08
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.26%
+5.06%
+11.88%
+1.85%
+0.63%
EXAS
Exact Sciences
$53.06
Chart
43.66
50.59
57.55
54.08
EXAS Latest Headlines
Exact Sciences Q1 Earnings: Decent Quarter But Growth Story Not Compelling.
Fri May 2, 2025
Cancer Diagnostic Firm Exact Sciences CEO Says Strong Q1 Paves Way For Transformative 2025 Lifts Annual Guidance. ) on Thursday reported a first-quarter 2025 EPS loss of 21 cents down from a 37-cent loss a year ago beating the analystThe company reported quarterly sales of $706.78 million up 11% year over year on a reported and core revenue basis beating the consensus.Screening revenue was $540 million an increase of 14% and Precision Oncology'.s revenue was $166.8 million an increase of 2%o
Fri May 2, 2025
EXAS Stock Up on Q1 Earnings & Revenue Beat 2025 Sales View Raised. Exact Sciences ends the first quarter of 2025 on a solid note.
Fri May 2, 2025
Exact Sciences Non-GAAP EPS of -$0.21 misses by $0.11 revenue of $706.79M beats by $18.16M.
Thu May 1, 2025
Exact Sciences Hikes Its Full-Year Outlook. But Theres One First-Quarter Drawback.. Exact Sciences hiked two elements of its outlook late Thursday despite coming in with a mixed earnings report.The post Exact Sciences Hikes Its Full-Year Outlook. But There'.s One First-Quarter Drawback. appeared first on Investor'.s Business Daily.
Thu May 1, 2025
Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine | DelveInsight. Global Molecular Diagnostics Market to Expand at a CAGR of ~9% by 2032 Due to the Rising Demand for Precision Medicine |. DelveInsightThe molecular diagnostics market is experiencing significant growth driven by advancements in technology increasing demand for personalized medicine and the rising prevalence of chronic diseases. Innovations such as next-genera
Thu May 1, 2025
[Latest] Global Multi Cancer Early Detection Market Size/Share Worth USD 5.09 Billion by 2034 at a 14.85% CAGR: Custom Market Insights (Analysis Outlook Leaders Report Trends Forecast Segmentation Growth Growth Rate Value). Multi Cancer Early Detection Market Size Trends and Insights By Type (Liquid Biopsy Gene Panel LDT (Laboratory Developed Tests) Others) By Price Point (Hospitals Diagnostic Laboratories Others) and By Region - Global Industry Overview Statistical Data Competitive Analysis Sha
Wed Apr 30, 2025
Exact Sciences (EXAS): Among Billionaire George Soros Small-Cap Stocks with Huge Upside Potential.
Thu Apr 24, 2025
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight. Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing |. DelveInsightThe liquid biopsy market size in cancer diagnostics is experiencing rapid growth due to advancements in non-invasive testing technologies. These tests which analyze blood or other bodily fluids for cancer-related biomarkers o
Wed Apr 23, 2025
EXAS Quantitative Stock Analysis - Benjamin Graham. Below is Valideas guru fundamental report for EXACT SCIENCES CORP (EXAS). Of the 22 guru strategies we follow EXAS rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B
Tue Apr 22, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
EXAS Stock trends
EXAS Stock performance
EXAS Stock analysis
EXAS investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Login to display Exact Sciences (EXAS) recommendation from the last 90 days from financial news and social media.
Hover over the category for more information
